Upgrades

Recommendation: We maintain our BUY recommendation on the stock and roll over our estimates to FY25.

Recommendation: We maintain our BUY recommendation on the stock and roll over our estimates to FY25.

ISGEC Heavy Engineering’s (ISGEC) Q4FY23 standalone revenue increased 4% YoY to Rs14bn aided by EPC revenue growth of 8% YoY whereas manufacturing segment revenue declined 4% YoY. Improvement in the share of high-margin manufacturing business led to marginal improvement in EBIDTA margin by 247bps YoY to 7.4%.

Mishra Dhatu Nigam’s (Midhani) Q4FY23 performance was impacted by higher raw
material costs. Key takeaways: 1) EBITDA margin rose 70bps QoQ to 29.1% despite firm raw material and power costs, owing to higher scrap utilisation; 2) orderbook at Mar’23-end was at Rs13.3 bn, aided by an inflow of Rs9bn during the quarter Q4FY23

Supriya Life Science reported a quarterly revenue growth of INR 1422.7 mn in Q4FY23, compared to INR 1051.0 mn in Q3FY23. The growth was primarily supported by strong traction in the US, Europe, and Latin America markets. Therapies such as Anti Anesthetic, Anti-Allergic, and Asthmatic played a key role in driving this growth.

For Q4FY23, BIL reported revenue of INR 23,170 mn (-2.4% YoY/ +7.0% QoQ). Sales volume was 72,676 MT, which was a decline of 5.8% YoY but an improvement of 9.3% QoQ. The Average Selling Price (ASP) per MT was higher by 3.6% YoY but contracted by 2.1% QoQ.

JK Cement’s (JKCE) Q4FY23 performance was impressive on multiple counts: a) grey cement volumes surged 17% YoY (similar to FY23); b) grey cement realisations rose 1.6% QoQ (~3% QoQ for the standalone entity) defying the industry trend of a marginal decline.